1. Home
  2. PHAR vs RYI Comparison

PHAR vs RYI Comparison

Compare PHAR & RYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHAR
  • RYI
  • Stock Information
  • Founded
  • PHAR 1988
  • RYI 1842
  • Country
  • PHAR Netherlands
  • RYI United States
  • Employees
  • PHAR N/A
  • RYI N/A
  • Industry
  • PHAR Biotechnology: Pharmaceutical Preparations
  • RYI Metal Fabrications
  • Sector
  • PHAR Health Care
  • RYI Industrials
  • Exchange
  • PHAR Nasdaq
  • RYI Nasdaq
  • Market Cap
  • PHAR 718.1M
  • RYI 699.3M
  • IPO Year
  • PHAR N/A
  • RYI N/A
  • Fundamental
  • Price
  • PHAR $10.27
  • RYI $23.32
  • Analyst Decision
  • PHAR Strong Buy
  • RYI Hold
  • Analyst Count
  • PHAR 3
  • RYI 1
  • Target Price
  • PHAR $30.00
  • RYI $25.00
  • AVG Volume (30 Days)
  • PHAR 4.3K
  • RYI 243.6K
  • Earning Date
  • PHAR 07-31-2025
  • RYI 07-29-2025
  • Dividend Yield
  • PHAR N/A
  • RYI 3.19%
  • EPS Growth
  • PHAR N/A
  • RYI N/A
  • EPS
  • PHAR N/A
  • RYI N/A
  • Revenue
  • PHAR $320,708,000.00
  • RYI $4,495,200,000.00
  • Revenue This Year
  • PHAR $13.31
  • RYI $0.35
  • Revenue Next Year
  • PHAR $7.68
  • RYI $3.40
  • P/E Ratio
  • PHAR N/A
  • RYI N/A
  • Revenue Growth
  • PHAR 24.13
  • RYI N/A
  • 52 Week Low
  • PHAR $6.65
  • RYI $17.18
  • 52 Week High
  • PHAR $12.61
  • RYI $27.41
  • Technical
  • Relative Strength Index (RSI)
  • PHAR 48.21
  • RYI 60.50
  • Support Level
  • PHAR $10.46
  • RYI $21.22
  • Resistance Level
  • PHAR $11.49
  • RYI $23.25
  • Average True Range (ATR)
  • PHAR 0.37
  • RYI 0.88
  • MACD
  • PHAR -0.12
  • RYI 0.32
  • Stochastic Oscillator
  • PHAR 27.62
  • RYI 94.09

About PHAR Pharming Group N.V.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

About RYI Ryerson Holding Corporation

Ryerson Holding Corp provides a metals service center, and value-added processor and is a distributor of industrial metals with operations in the United States, Canada, and Mexico. In addition to its North American operations, it conducts processing and distribution operations in China. Its customers range from local, independently owned fabricators and machine shops to large, international original equipment manufacturers. It carries a full line of products in stainless steel, aluminum, carbon steel, and alloy steels and a limited line of nickel and red metals in various shapes and forms. The company generates substantially all of its revenue from sales of metal products. Geographically, the majority revenue is generated from the United States.

Share on Social Networks: